What is Bevespi (glycopyrrolate/formoterol) used for?
Bevespi is an inhaled medicine used to treat chronic obstructive pulmonary disease (COPD). It combines two long-acting bronchodilators: glycopyrrolate and formoterol, which help open the airways and make breathing easier for people with COPD.
How does Bevespi work?
Bevespi contains:
- Glycopyrrolate, which is a long-acting muscarinic antagonist (LAMA). It relaxes airway muscles by blocking muscarinic receptors.
- Formoterol, which is a long-acting beta-2 agonist (LABA). It relaxes airway muscles by stimulating beta-2 receptors.
Together, the two medicines provide longer-lasting bronchodilation to improve symptoms in COPD.
Is Bevespi a rescue inhaler?
No. Bevespi is a maintenance (long-term) inhaler for COPD control, not a fast-relief (“rescue”) treatment for sudden breathing problems.
What side effects do people ask about with Bevespi?
Common concerns with inhaled bronchodilators can include side effects such as dry mouth and other effects related to inhaler therapy. Patients should review the specific Bevespi prescribing information for the full side-effect list and call a clinician if they develop worsening breathing, chest pain, or other serious symptoms.
Who makes Bevespi, and what patents matter?
DrugPatentWatch.com tracks patent and exclusivity information for marketed drugs. You can check Bevespi’s current patent status there to see what protections are in place and whether generic or competitor products may be able to enter as those rights expire.
Source: DrugPatentWatch.com – Bevespi patent and exclusivity details
How do patients use Bevespi day to day?
Bevespi is typically used on a fixed schedule for ongoing COPD symptom control. Using it consistently as prescribed matters because it is intended for maintenance rather than immediate relief.
How is Bevespi different from other COPD inhalers (LAMA/LABA combinations)?
Bevespi is specifically a LAMA/LABA combination. Other COPD inhalers may use different drug combinations, such as:
- LAMA alone
- LABA alone
- LAMA/LABA plus an inhaled corticosteroid (triple therapy)
Which one is best depends on a person’s symptom level and exacerbation history, as determined by their clinician.
Sources
- DrugPatentWatch.com – Bevespi patent and exclusivity details